Peptide therapy in Australia is not bulk-billed and is generally not covered by private health insurance. You pay the doctor, the compounding pharmacy, and (sometimes) the pathology lab directly. Here is the realistic 2026 cost structure for an Australian patient going through a regulated TGA SAS-B pathway.
Telehealth consultation: $99 for the initial review with an AHPRA-registered Australian doctor. Follow-up consults are typically $59–$79 depending on the practice. Some prescribers bundle the first three months of follow-up into the initial fee.
Pathology (if required): $80–$180 out-of-pocket for baseline bloods (full blood count, liver and kidney function, lipid panel, HbA1c, hormones depending on indication). If your GP has run these in the last 6 months, they may be reusable.
Compounded peptide: varies significantly by molecule and dose. As a 2026 rough guide, monthly compounded peptide cost from a TGA-licensed Australian pharmacy is approximately $180–$320 for BPC-157, $220–$380 for a CJC-1295 / Ipamorelin blend, $260–$420 for AOD-9604, and $450–$900+ for tirzepatide depending on titration dose. These prices include pharmacy compounding, batch testing, and standard supplies (vials, syringes, alcohol swabs).
Free guide: Legal Peptides in Australia (2026)
What's legal under TGA SAS-B, which peptides Australian doctors actually prescribe, real costs, and the questions to ask at your consult.
No spam. Unsubscribe any time. See our privacy policy.
Shipping: $15–$25 cold-chain courier within Australia. Most pharmacies ship Monday–Wednesday only to avoid weekend transit.
Realistic monthly total for someone newly starting therapy: $300–$500 for a recovery / soft-tissue protocol (BPC-157), $350–$600 for a GH-secretagogue blend (CJC-1295 + Ipamorelin), or $600–$1,000 for tirzepatide weight management at therapeutic doses. The first month is usually 20–30% higher because of the initial consult and baseline pathology.
What you are NOT paying for inside that price: smuggled "research peptide" lottery (substituted molecules, no potency assay, customs seizure risk), and no one to call when something feels wrong. The premium for going local is the regulated system around the vial — AHPRA-registered prescriber, TGA SAS-B notification, PIC/S-GMP compounding pharmacy, adverse-event pathway.
If price is a hard constraint, ask the prescriber about lower-cost alternatives within the same therapeutic class, or about whether a shorter cycle is clinically reasonable for your goal.